eCommons@AKU
Department of Biological & Biomedical
Sciences

Medical College, Pakistan

1-29-2021

Meropenem-induced pancytopenia in a preterm neonate: A case
report
Kashif Hussain
Aga Khan University, kashif.hussain@aku.edu

Muhammad Sohail Salat
Aga Khan University, muhammad.salat@aku.edu

Naureen Mohammad
Aga Khan University, naureen.mohammad@aku.edu

Ambreen Mughal
Aga Khan University, ambreen.mughal@aku.edu

Sidra Idrees
Aga Khan University, sidra.idrees@aku.edu

See next page for additional authors

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs
Part of the Maternal and Child Health Commons, Pediatrics Commons, Pharmacy and Pharmaceutical
Sciences Commons, and the Women's Health Commons

Recommended Citation
Hussain, K., Salat, M. S., Mohammad, N., Mughal, A., Idrees, S., Iqbal, J., Ambreen, G. (2021). Meropeneminduced pancytopenia in a preterm neonate: A case report. Journal of Medical Case Reports, 15(1), 25.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs/901

Authors
Kashif Hussain, Muhammad Sohail Salat, Naureen Mohammad, Ambreen Mughal, Sidra Idrees, Javaid
Iqbal, and Gul Ambreen

This case report is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_bbs/901

(2021) 15:25
Hussain et al. J Med Case Reports
https://doi.org/10.1186/s13256-020-02632-1

Open Access

CASE REPORT

Meropenem‑induced pancytopenia
in a preterm neonate: a case report
Kashif Hussain1, Muhammad Sohail Salat2, Naureen Mohammad1, Ambreen Mughal1, Sidra Idrees2,
Javaid Iqbal2 and Gul Ambreen1*

Abstract
Background: A post-marketing surveillance study has reported an association between meropenem use and the
incidence of hematologic abnormalities, including leukopenia, thrombocytopenia, hemolysis, and neutropenia, but
the precise incidence in neonates is unknown. Here, we report meropenem-induced pancytopenia in a preterm
neonate.
Case presentation: A preterm newborn Pakistani received intravenous meropenem 40 mg/kg every 8 hours to treat
Klebsiella pneumoniae in blood cultures and suspected meningitis. The baby developed severe thrombocytopenia,
with a platelet count of 22 × 103 cells/mm3, low hemoglobin level of 9.7 g/dl, and low absolute neutrophil count
(ANC) of 816 cells/mm3 on days 3, 14, and 17 of meropenem therapy, respectively. Based on the blood culture and
institutional guidelines, meropenem treatment was continued with monitoring and supportive care for a total of 19
days. After discontinuation of meropenem, the baby was monitored continuously for hematological changes, and
low counts persisted for 3 days. ANC improved to > 1500 cells/mm3 on the fourth day, and the platelet count reached
> 150 × 103 cells/mm3 for the first time on the seventh day of meropenem discontinuation. All subsequent complete blood count (CBC) reports showed improving trends. The baby was discharged on the 48th day of life (DOL),
with follow-up monitoring of CBC. The baby was kept on iron supplements, and hemoglobin level of 11.2 g/dl was
observed on the 59th DOL.
Conclusion: Neonatal pancytopenia may lead to serious health complications; therefore, clinicians and pharmacists
need to vigilantly monitor CBC in this vulnerable population, even when administering meropenem in septic doses
for the recommended duration.
Keywords: Meropenem, Preterm neonate, Pancytopenia, Absolute neutrophil count, Hematological problems
Background
Pancytopenia is defined as reduced white blood cell
(WBC) count, hemoglobin, and platelet count. Pancytopenia occurs when hemoglobin is < 13 g/dl in
males and < 12 g/dl in females, absolute neutrophil
count (ANC) is < 1500 cells/mm3, and platelet count is
< 150 × 103 cells/mm3 [1]. Pancytopenia is considered
*Correspondence: gul.ambreen@aku.edu
1
Department of Pharmacy, Main Pharmacy Aga Khan University Hospital,
Stadium Road, P.O Box 3500, Karachi 74800, Pakistan
Full list of author information is available at the end of the article

severe if a patient experiences two or more of the following: hemoglobin < 7 g/dl, ANC < 500 cells/mm3,
and platelet count < 50 × 103 cells/mm3. The mechanism underlying pancytopenia mainly involves bone
marrow infiltration, bone marrow aplasia, and blood
cell destruction that results in peripheral blood leakage [1]. Suppression of bone marrow varies widely in
the pediatric population but may occur due to toxins,
infection, or malignant cell infiltrates that can lead to
hypocellular bone marrow function. Drug-induced
pancytopenia is also a rare but secondary cause of
bone marrow suppression due to direct bone marrow
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toxicity, immune-mediated (complement or antibodymediated) cell destruction, and hapten formation, and
directly affects myeloid precursors [2, 3]. An in vitro
study of several beta-lactam antibiotics established the
presence of well-differentiated myeloid cells and copious granulocyte precursors along with dose-dependent
suppression of granulopoiesis [4]. Antibody-mediated
hemolytic anemia and thrombocytopenia have also
been established in meropenem-treated patients [5, 6].
Several medications can cause pancytopenia including chemotherapeutics, antiepileptics, antidepressants,
and antibiotics [3, 5, 7]. A case–control epidemiological surveillance study was conducted over a follow-up
period of 78.7 million person-years to assess the incidence of drug-induced agranulocytosis. Around 396
confirmed cases of acute neutropenia were observed,
with an overall incidence of 3.5:1 million per year [8].
It was found that agranulocytosis clearly increased the
risk of mortality, with a fatality rate of 9.1%. The most
common drugs causing agranulocytosis were dipyrone (16%), beta-lactam antibiotics (12.0 %), ticlopidine (11.1%), antithyroid drugs (7.2%), and sulfonamide
antibiotics (5.4%) [8].
Meropenem is one of the beta-lactam antibiotics that
can cause serious and life-threatening neutropenia. It
is a bactericidal broad-spectrum antibiotic with grampositive, gram-negative, and anaerobic coverage, and is
mainly used in the treatment of severe gram-negative
infections in neonates including severe sepsis, meningitis, and complicated intra-abdominal infections such
as necrotizing enterocolitis (NEC), one of the most
common gastrointestinal emergencies and a major
cause of morbidity and mortality in preterm neonates.
For improved clinical outcomes, early recognition and
aggressive management with broad-spectrum or combination antimicrobial agents is most often undertaken
to treat NEC [9]. Because of its broad-spectrum activity, meropenem is an agent of great utility [10]. Based
on the increasing trends of morbidity and mortality due
to multidrug-resistant gram-negative bacterial infections in our neonatal intensive care unit (NICU), and
following institutional guidelines, other antibiotics
such as vancomycin and colistin are also used [11–13]
after infectious disease (ID) consultation. The most
common adverse effects of meropenem are constipation or diarrhea, nausea, vomiting, rashes, and diaperarea moniliasis in pediatric patients [14]. Some cases of
meropenem-induced neutropenia have been reported
[15]. However, no known case of meropenem-induced
pancytopenia in neonates has yet been published. Here
we report an event of meropenem-induced pancytopenia in a neonate admitted to the NICU of a tertiarycare hospital.
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Case presentation
A newborn Pakistani baby was transferred to the intensive care unit due to prematurity, low birth weight, and
intrauterine growth retardation. Her birth weight was
0.71 kg and APGAR scores were 3 at 1 minute and 4 at
5 minutes. Delivered by emergency C-section at 29 weeks
due to raised blood pressure and fetal distress, she was
initially kept on continuous positive airway pressure
(CPAP) and given nothing through the mouth, and total
parenteral nutrition (TPN) was started. Caffeine was
loaded at 20 mg/kg and continued as the standard of care
for apnea of prematurity. A prophylactic dose of 1 mg of
vitamin K was given. During the first 24 hours, complete
blood count (CBC) results were WBC of 18.3 × 103 cells/
mm3, ANC of 1244 cells/mm3, platelet count of 166 × 103
cells/mm3, and hemoglobin of 17.8 g/dl. On the second
day of life (DOL), ampicillin and gentamicin were started
as empirical therapy, and the CBC report showed WBC
4 × 103 cells/mm3, ANC of 760 cells/mm3, platelet count
of 152 × 103 cells/mm3, and hemoglobin of 15.9 g/dl. In
addition, fluconazole was started as antifungal prophylaxis. The patient was given phototherapy. Chest X-ray
and ultrasound of the head were performed, with normal
findings. CPAP was tapered to high flow on merit, and
blood culture was sent.
On the fourth DOL, the baby developed issues of severe
respiratory distress and abdominal distension along with
metabolic acidosis. She was intubated and kept on synchronized intermittent mandatory ventilation (SIMV)
mode. The CBC results showed ANC of 912 cells/mm3,
platelet count of 99 × 103 cells/mm3, and hemoglobin of
12.7 g/dl. Inotropic support was started, and antibiotics
were escalated to meropenem 20 mg/kg every 12 hours,
vancomycin 10 mg/kg once daily, and colistin at a loading
dose of 5 mg/kg with a maintenance dose of 1.5 mg/kg
every 12 hours. Blood culture showed no growth. After
ID consult, vancomycin was discontinued on the third
day and a decision was made to continue meropenem
and colistin [11–13] to manage NEC and sepsis.
On the fifth DOL, echocardiogram was performed and
showed patent ductus arteriosus (PDA) of 3 mm with
severe persistent pulmonary hypertension of the newborn (PPHN). Acetaminophen was started for the next 5
days. On the sixth day of meropenem therapy, the platelet count dropped to 42 × 103 cells/mm3, treated in line
with sepsis-associated thrombocytopenia [16], and managed by transfusion of 10 ml/kg platelet units [17]. Meropenem and colistin were discontinued on the eighth day
of therapy, and trophic feeding was started. An echocardiogram was repeated on day 11, which showed a closed
PDA and moderate PPHN. On the 18th DOL, the child
was successfully extubated and kept on high-flow oxygen.
There was slow progress in feeding.
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On the 22nd DOL, the baby had tachycardia and an
episode of 99.7 °F fever. Thus, septic workup was done
and showed WBC count of 17.4 × 103 cells/mm3, ANC of
12,632.4 cells/mm3, and platelets of 203 × 103 cells/mm3.
C-reactive protein (CRP) was 77 mg/l and renal function
was normal (blood urea nitrogen [BUN] of 11 mg/dl and
creatinine of 0.2 mg/dl). Meropenem was started in meningitic doses of 40 mg/kg every 8 hours [10] along with
vancomycin 15 mg/kg every 12 hours.
In the microbiological investigation, urine and cerebrospinal fluid (CSF) cultures were found to be negative, but
the blood culture was positive for Staphylococcus species
(not aureus). Blood culture repeated after 48 hours was
positive for carbapenem-sensitive Klebsiella pneumoniae.
The baby was moved to the isolation room. On the 24th
DOL, the baby developed severe thrombocytopenia, with
a platelet count of 22 × 103 cells/mm3, managed with the
transfusion of 10 ml/kg platelet units [17].
On the 25th DOL, an episode of generalized tonicclonic fit occurred for which single-dose diazepam and a
loading dose of phenobarbitone were given initially and
then continued with maintenance doses of phenobarbitone. Due to significant metabolic acidosis and desaturation, the baby was re-intubated. After ID consult,
meropenem was continued in meningitic doses and vancomycin was discontinued. SIMV and a central line were
placed. TPN was started with nothing per oral status.
Blood gases were monitored, and the baby was extubated after 4 days and switched to CPAP. Phenobarbitone
was discontinued after 6 days of therapy, and the baby
was seizure-free through the remainder of the hospital stay. All repeat blood cultures were negative for any
growth including CSF culture. The ID team was on board
and decided to continue meropenem for a total of 14 days
post-negative culture in septic doses of 20 mg/kg, and
vancomycin was discontinued after 6 days. All repeated
blood cultures obtained on the 27th and 30th DOL confirmed no pathogenic growth.
On the 33rd DOL, the CBC report showed WBC of
8.7 × 103 cells/mm3, ANC of 4576 cells/mm3, platelets of 78 × 103 cells/mm3, and hemoglobin of 10.8 g/
dl. On the 36th DOL, the CBC report showed WBC of
5.1 × 103 cells/mm3, ANC of 2917 cells/mm3, platelets
of 29 × 103 cells/mm3, and hemoglobin of 9.2 g/dl. The
baby was managed for thrombocytopenia with platelet
transfusion.
On the 37th DOL, hemoglobin dropped to 8.3 g/
dl in the evening, and platelet count improved to
63 × 103 cells/mm3, WBC was 4.8 × 103 cells/mm3, and
ANC was 1285 cells/mm3. On the 39th DOL, a marked
reduction was observed in ANC to 816 cells/mm3, platelets of 38 × 103 cells/mm3, and hemoglobin of 8.3 g/dl,
and the baby received blood transfusion to manage it. For
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constant issues, a hematological consult was taken and a
decision was made to manage the baby symptomatically
with 10 ml/kg platelet units at a platelet count < 50 [17]
and 15 ml/kg packed cell transfusion at hemoglobin < 10
g/dl [18].
On the 40th DOL, meropenem was discontinued 14
days after negative culture (total of 19 days of meropenem therapy). On the same day the platelet count
was 34 × 103 cells/mm3, ANC was 818 cells/mm3, and
hemoglobin was 10.2 g/dl, and the baby was transfused
to manage these issues. After discontinuation of meropenem, the baby was continuously monitored for hematological changes, and low counts persisted for 3 days.
Improved ANC of > 1500 cells/mm3 was reported on the
fourth day, and platelet count of > 150 × 103 cells/mm3
was reported for the first time on the sixth day of meropenem discontinuation, but hemoglobin was still low
(Fig 1). CPAP was tapered gradually to nasal prongs. The
peripherally inserted central catheter was removed, and
orogastric (OG) tube feeding was commenced. The baby
was discharged on the 48th DOL on iron supplements
with follow-up monitoring of CBC. Hemoglobin level of
11.2 g/dl was found on the 59th DOL.

Discussion
Drug-induced pancytopenia is a rare hematological
problem in neonatal clinical practices, evaluated based
on a complete underlying pathological history, physical
examination, and vigilant interpretation of biochemical,
radiological, histopathological, and hematological findings [19]. Concerns have been raised about hematological
adverse effects of several beta-lactamase inhibitors [8].
This neonatal case documents meropenem-induced pancytopenia and emphasizes cautious laboratory monitoring for patients receiving meropenem therapy.
Sepsis is another known etiology of pancytopenia.
Although the neonate in the present case had a blood
culture positive for K. pneumoniae, the results of all
repeated blood cultures were negative, showing the
resolution of sepsis. Van Tuyl et al. [20] also reported a
case of a neonate receiving meropenem in meningitic
doses of 40 mg/kg/day to treat meropenem-susceptible
Enterobacter cloacae in blood culture. The baby developed meropenem-induced neutropenia on the 13th day
of therapy, with ANC of 288 cells/mm3. The decision
was made to discontinue meropenem on the 19th day
of therapy instead of the initially planned 21 days. In the
present case, the baby continued to receive meropenem
treatment and was managed for hematological problems
based on institutional guidelines and culture sensitivity.
Initially, hematological changes were not considered as
directly meropenem-induced.
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Phenobarb
Vancomycin
Meropenem
Fluconazole
Fig. 1. Hematological changes and timing of medication during hospitalization

Recently published reports also support the notion
of carbapenem-induced hematological disorders. A
case report by Estella and colleagues [21] described
meropenem-induced pancytopenia in a 3-year-old
patient at 100 mg/kg given every 8 hours to manage the
regrowth of meropenem-sensitive Morganella morganii in CSF cultures. Huang et al. [6] reported a case of
meropenem-induced immune thrombocytopenia in a
59-year-old patient, by detecting meropenem-dependent platelet antibodies and platelet count recovery after
discontinuation of meropenem. Oka et al. [5] reported
the development of severe anemia with clinical signs in
a 76-year-old female patient, who received 2 g meropenem per day. On further investigation, they found that
a direct antiglobulin test (DAT) was positive for immunoglobulin G (IgG) and C3d, and reported the presence
of meropenem-dependent antibodies in the patient’s
serum [5].
The absence of drug-dependent antibody testing and
bone marrow aspiration prevent us from drawing a firm
conclusion regarding the mechanism of meropeneminduced pancytopenia in the present case. However, the
hematological findings with the progressive development of thrombocytopenia, anemia, and then neutropenia suggest a possible mechanism of suppression of

granulopoiesis or antibody-mediated destruction, as
reported in recent studies [5, 6].
During hospitalization, the neonate received other
medications, which have been reported to exert hematological effects. The baby initially received ampicillin, gentamicin, and fluconazole, and then received meropenem,
colistin, vancomycin, and phenobarbital. However, severe
thrombocytopenia developed on the sixth day of the first
course of meropenem therapy, when the baby was also
on colistin and fluconazole. This issue was resolved when
meropenem was discontinued. During the second course
of meropenem therapy, the baby again developed severe
thrombocytopenia on the third day, while also receiving
vancomycin, fluconazole, and phenobarbital. Phenobarbital-induced hematological abnormalities are reported
in animal and adult studies [22, 23], and therefore it was
discontinued on the sixth day. No seizures were observed
but counts did not improve. However, the baby developed severe anemia and neutropenia while receiving
fluconazole and meropenem only. After meropenem discontinuation, severe anemia and neutropenia showed a
resolving trend for 3 days. Severe neutropenia resolved
on the fourth day, and hemoglobin was reported at > 10
g/dl without transfusion on the seventh day of meropenem discontinuation, while fluconazole therapy was
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continued from the beginning until the 56th DOL, which
further confirms the association of meropenem-induced
hematological changes in this baby. It was also confirmed
that the baby did not experience any additional infection
even though she was not discharged on any antibiotic,
which correlates with the fast recovery of blood counts
after meropenem discontinuation.

Conclusions
In the present neonatal case, the gradual onset of hematological irregularities correlates with the commencement of meropenem therapy, and our observations
are also verified by previously published evidence. The
follow-up CBC count further established the resolution
of pancytopenia after discontinuation of meropenem.
Neonatal pancytopenia may lead to serious health complications; therefore, clinicians and pharmacists need to
vigilantly monitor CBC counts in this vulnerable population, even when administering meropenem in septic
doses for the recommended duration.
Patient perspective

From the perspective of the patient’s father, it was a rare
case to have such kind of adverse events in a neonate
with the normal treatment regimen. He was shared about
all the events and he admired the team for the timely and
effectively managing the issues and finally 100% recovery
on the follow-ups.
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